Human RPE65 Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year

Human gene therapy with rAAV2-vector was performed for the RPE65 form of childhood blindness called Leber congenital amaurosis. In three contemporaneous studies by independent groups, the procedure was deemed safe and there was evidence of visual gain in the short term. At 12 months after treatment,...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Cideciyan, Artur V., Hauswirth, William W., Aleman, Tomas S., Kaushal, Shalesh, Schwartz, Sharon B., Boye, Sanford L., Windsor, Elizabeth A.M., Conlon, Thomas J., Sumaroka, Alexander, Pang, Ji-jing, Roman, Alejandro J., Byrne, Barry J., Jacobson, Samuel G.
Format: Artigo
Język:Inglês
Wydane: Mary Ann Liebert, Inc. 2009
Hasła przedmiotowe:
Brief Reports
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2829287/
https://ncbi.nlm.nih.gov/pubmed/19583479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hum.2009.086
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy